Business Context and Reporting Period
Company: Tempus AI, Inc. (Nasdaq: TEM)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Tempus AI is a healthcare technology company combining laboratory testing with artificial intelligence to improve patient care. The company operates as a single segment, deriving revenue primarily from Genomics (clinical testing) and Data and Services (licensing de-identified data and clinical trial support).
Key Event: On February 3, 2025, the company completed the acquisition of Ambry Genetics Corporation, significantly expanding its hereditary cancer screening capabilities.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Net Revenue | $314.6 million | $570.4 million |
| Net Loss | $(42.8) million | $(110.9) million |
| Loss from Operations | $(61.8) million | $(130.5) million |
| Adjusted EBITDA | $(5.6) million | $(21.8) million |
| Cash and Cash Equivalents | $186.3 million | $186.3 million (as of period end) |
| Total Debt (Long-term + Revolving) | $798.0 million | $798.0 million (as of period end) |
| Stockholders' Equity | $309.6 million | $309.6 million (as of period end) |
Note: Total Debt includes $471.7 million in long-term debt, $226.3 million in convertible promissory notes, and $100.0 million in revolving credit facility borrowings.
Material Changes vs. Prior Period
- Revenue Growth: Total net revenue increased 90% year-over-year (YoY) for the quarter and 83% YoY for the six-month period.
- Genomics: Revenue surged 115% YoY to $241.8 million (Q2) and 103% YoY to $435.6 million (6M), driven by the Ambry acquisition (adding hereditary testing) and increased oncology test volume.
- Data and Services: Revenue grew 36% YoY to $72.8 million (Q2) and 39% YoY to $134.7 million (6M), primarily due to increased demand for Insights products and the Pathos Foundation Model agreement.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased 61% YoY to $180.7 million (Q2) and 38% YoY to $335.3 million (6M). This significant reduction is primarily attributable to a decrease of $362.4 million in stock-based compensation expenses related to RSUs that vested in connection with the IPO in the prior year.
- Profitability Improvement: Net loss narrowed significantly from $(552.2) million in Q2 2024 to $(42.8) million in Q2 2025, driven by revenue growth and the reduction in non-cash stock-based compensation.
- Balance Sheet Expansion: Total assets increased from $926.1 million (Dec 31, 2024) to $1.63 billion (June 30, 2025), largely due to the acquisition of Ambry (adding $231.2 million in goodwill and significant intangible assets).
Guidance, Outlook, and Risks
- Capital Raise (Subsequent Event): On July 3, 2025, the company completed a private offering of $750.0 million in 0.75% Convertible Senior Notes due 2030. Net proceeds were approximately $725.9 million.
- Proceeds were used to repay $293.5 million of Term Loan Facilities and pay $41.8 million for capped call transactions.
- Remaining proceeds are designated for general corporate purposes, including acquisitions and working capital.
- Outlook: Management expects to incur additional operating losses in the near future as it continues to invest in product innovation, sales expansion, and marketing. The company believes current cash, cash equivalents, and marketable securities are sufficient to fund operations for at least 12 months.
- Risks and Contingencies:
- Legal Proceedings: The company is involved in patent infringement litigation with Guardant Health Inc. and a federal securities class-action lawsuit filed in June 2025 alleging false or misleading statements regarding business operations.
- Reimbursement: Financial performance relies heavily on reimbursement rates from commercial payers and government programs (Medicare/Medicaid). Changes in medical policies could significantly impact results.
- Debt Covenants: The company must maintain minimum liquidity of $25 million and meet specific consolidated revenue thresholds ($1.0 billion trailing twelve months for 2025) to remain in compliance with its Credit Agreement.
Investor Verification Checklist
- Acquisition Integration: Verify the realization of synergies and revenue contribution from the Ambry Genetics acquisition, which drove the majority of Q2 Genomics growth.
- Stock-Based Compensation Normalization: Assess future expense trends, noting that the massive decrease in SG&A was largely due to the one-time vesting of IPO-related RSUs in the prior year; future periods may see higher normalized stock-based compensation.
- Debt Structure: Review the terms of the new $750 million Convertible Senior Notes and the impact of the capped call transactions on potential future dilution.
- Reimbursement Rates: Monitor updates on Medicare and Medicaid reimbursement rates for oncology tests, as average revenue per test is a key driver of Genomics margins.
- Legal Exposure: Track the status of the Guardant Health patent litigation and the securities class-action lawsuit for potential financial impact.